argenx announces Extraordinary General Meeting of Shareholders on December 12, 2022
Amsterdam, the Netherlands
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an extraordinary general meeting of shareholders will be held at 12:00 AM CET on Monday, 12 December, 2022 at Hilton Hotel Schiphol, Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.
The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website on www.abnamro.com/evoting.
The sole agenda item will be the proposed appointment of Mrs. Ana Cespedes as non-executive director of the Company.
The full agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing [email protected] About argenx argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation. The Company will provide a live audio-webcast of the general meeting to enable as many shareholders as possible to attend.
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact: